Breaking Down De Rucci Healthy Sleep Co., Ltd. Financial Health: Key Insights for Investors

De Rucci Healthy Sleep Co., Ltd. presents a mixed but instructive financial profile for investors: trailing twelve-month revenue stood at CNY 5.49 billion (down 2.92% YoY) while Q3 2025 revenue grew 2.79% to CNY 1.28 billion, annual 2024 revenue was CNY 5.60 billion after a volatile five-year run that included a 45.56% surge in 2022 and a 10.31% drop in 2023; profitability remains notable with net income of CNY 711.92 million (net margin ~12.98%), EPS of CNY 1.65 and an ROE of 16.17%, operational efficiency shown by an operating margin of 13.08% and EBITDA margin of 17.06%, and a shareholder-friendly dividend yield of 6.55% (CNY 1.82 per share); balance sheet strength is evident with total assets of CNY 7.50 billion, total liabilities of CNY 3.00 billion, cash and equivalents of CNY 3.48 billion producing a net cash position of CNY 2.08 billion, a conservative debt-to-equity ratio of 0.32 and an Altman Z-Score of 3.89; valuation metrics show a trailing P/E near 16-17, P/S of 2.02 and EV/EBITDA of 10.44 while growth catalysts include a recent SG$46 million acquisition to expand overseas production, AIoT mattress R&D and analyst forecasts of ~9.6% EPS and 8.4% revenue CAGR-read on for a detailed breakdown of revenue, profitability, liquidity, valuation and risks to decide whether 001323.SZ fits your portfolio.

De Rucci Healthy Sleep Co., Ltd. (001323.SZ) - Revenue Analysis

• Recent top-line movement: TTM revenue of CNY 5.49bn represents a modest contraction (-2.92%) versus the prior 12‑month period, while Q3 2025 showed sequential YoY recovery (+2.79%).
• Historical volatility: a sharp expansion in 2022 (+45.56%) was followed by a substantive pullback in 2023 (-10.31%), indicating sensitivity to market cycles, channel mix and/or one‑off effects.
• Productivity and scale: revenue per employee of ~CNY 1.06m with a 5,188-strong workforce suggests mid-range operational leverage for a consumer durables brand.
• Valuation context: market cap CNY 11.08bn and P/S 2.02 imply investor pricing roughly twice trailing sales - useful for cross‑peer comparisons in mattress and home furnishings sectors.

De Rucci Healthy Sleep Co., Ltd. (001323.SZ) Profitability Metrics

For the trailing twelve months ending September 30, 2025, De Rucci Healthy Sleep Co., Ltd. (001323.SZ) demonstrates solid profitability and shareholder returns supported by efficient operations and conservative leverage.

• Net income (TTM to 2025-09-30): CNY 711.92 million
• Net profit margin: 12.98%
• Earnings per share (EPS, TTM): CNY 1.65
• Trailing P/E ratio: 15.49
• Return on equity (ROE): 16.17%
• Operating margin: 13.08%
• EBITDA margin: 17.06%
• Dividend yield: 6.55% (annual dividend CNY 1.82 per share)
• Interest coverage ratio: 35.61

For contextual background on the company's strategy, ownership and how it generates revenue, see: De Rucci Healthy Sleep Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

De Rucci Healthy Sleep Co., Ltd. (001323.SZ) Debt vs. Equity Structure

• Debt-to-Equity Ratio: 0.32 - conservative leverage profile
• Total Debt: CNY 1.40 billion
• Total Equity: CNY 4.42 billion
• Total Assets: CNY 7.50 billion
• Total Liabilities: CNY 3.00 billion
• Cash & Cash Equivalents: CNY 3.48 billion
• Net Cash Position: CNY 2.08 billion (cash minus debt)
• Interest Coverage Ratio: 35.61 - strong ability to cover interest expenses

De Rucci Healthy Sleep Co., Ltd. (001323.SZ) - Liquidity and Solvency

• Current ratio: 1.42 - adequate short-term liquidity to cover near-term liabilities.
• Quick ratio: 1.24 - sufficient ability to meet immediate obligations without relying on inventory.
• Working capital: CNY 1.24 billion - positive operational liquidity available for day-to-day needs.
• Net cash per share: CNY 4.81 - per-share cash buffer that enhances financial flexibility.
• Total liabilities: CNY 3.00 billion vs. total assets: CNY 7.50 billion - equity base provides a solid asset coverage.
• Altman Z-Score: 3.89 - indicates a low risk of bankruptcy under the classic model.

De Rucci Healthy Sleep Co., Ltd. (001323.SZ) - Valuation Analysis

Key valuation metrics for De Rucci Healthy Sleep Co., Ltd. provide a snapshot of how the market prices the company relative to earnings, book value and cash generation.

• Trailing P/E: 16.78 - market paying ~16.8x last 12 months' earnings.
• Forward P/E: 15.58 - expected earnings growth is priced in, modestly cheaper than trailing.
• Price-to-Book (P/B): 2.71 - trading at a premium to book value.
• EV/EBITDA: 10.44 - enterprise-level valuation relative to operating profitability.
• EV/FCF: 16.06 - valuation relative to free cash flow generation.
• PEG: not available - limits a growth-adjusted P/E assessment.

Interpretation highlights:

• The P/E levels (~15-17x) indicate a reasonable market valuation relative to earnings, neither deeply discounted nor exuberant versus typical consumer discretionary peers.
• A P/B of 2.71 signals investors pay a premium to net book value, reflecting intangible brand strength and expected future profitability.
• EV/EBITDA near 10.4 and EV/FCF at 16.1 show the company is valued at healthy multiples of operating cash profits and free cash flows; investors should compare these to sector medians for context.
• The absence of a PEG ratio means investors must pair P/E with explicit growth forecasts to assess valuation vs growth trade-offs.

For additional background on the company, see: De Rucci Healthy Sleep Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

De Rucci Healthy Sleep Co., Ltd. (001323.SZ) - Risk Factors

• Revenue volatility: Trailing twelve months revenue declined by 2.92% (period ending 2025-09-30), signaling exposure to demand fluctuations and pricing pressures.
• Profitability pressure: Net profit margin eased from 13.08% in the prior quarter to 12.98%, suggesting narrowing margins that could worsen if cost or input prices rise.
• Leverage and interest risk: Debt-to-equity ratio of 0.32 indicates moderate leverage; while current interest coverage is strong at 35.61, rising debt or lower operating income could reduce this cushion.
• Bankruptcy risk: Altman Z‑Score of 3.89 places the company in a low bankruptcy-risk zone, but macroeconomic shocks or sector downturns could change that assessment.
• Market-cap and volatility: Market capitalization of CNY 12.00 billion classifies De Rucci as mid-cap, which historically can experience greater price volatility than large-cap peers.
• External dependency: Sensitivity to consumer discretionary spending, supply-chain disruptions, and raw-material costs present ongoing risks to sales and margins.
• Competitive landscape: Intensifying competition in the bedding and sleep products market could pressure market share and average selling prices.

• Cash-flow sensitivity: Negative swings in operating cash flow could force reliance on debt or equity issuance, diluting shareholders or increasing interest burden.
• Interest-rate and refinancing risk: If rates rise or access to capital tightens, the company's cost of capital and ability to refinance could be impaired despite current coverage.
• Regulatory and regional risk: Changes in trade policy, tariffs, or region-specific demand (domestic vs. export) could materially affect revenue streams.

De Rucci Healthy Sleep Co., Ltd. (001323.SZ) - Growth Opportunities

Analyst consensus and recent strategic moves point to measurable growth vectors for De Rucci Healthy Sleep Co., Ltd. over the next several years, driven by product innovation, geographic expansion and targeted M&A.

• Analysts forecast earnings growth of 9.6% per annum and revenue growth of 8.4% per annum over the next three years.
• Return on equity (ROE) is forecasted to reach 16.2% in three years, suggesting improving capital efficiency and profitability.
• December 2024 acquisition: Mattress International and assets from PT Tai Cheng Development for SG$46 million to expand overseas production base and market share.
• Ongoing R&D investments including launch of the company's first AIoT mattress to bolster premium product offerings and differentiation.
• International expansion provides revenue diversification and exposure to higher-margin premium markets.

Key metrics and deal facts at a glance:

• Market positioning: emphasis on premium sleep solutions and quality control aligns with rising global demand for health- and tech-enabled bedding.
• Operational leverage: overseas production capacity from the SG$46M acquisition can improve gross margins if ramped efficiently.
• R&D-driven differentiation: AIoT and smart-sleep features create higher ASP (average selling price) potential and recurring-service opportunities.

For background on corporate history and business model, see: De Rucci Healthy Sleep Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money